Suppr超能文献

本美司他滨、安罗替尼联合化疗治疗广泛期小细胞肺癌的随机 3 期临床试验。

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.

机构信息

Jilin Cancer Hospital, Changchun, China.

Hunan Cancer Hospital, Changsha, China.

出版信息

Nat Med. 2024 Oct;30(10):2967-2976. doi: 10.1038/s41591-024-03132-1. Epub 2024 Jul 11.

Abstract

Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining the regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial that investigated the efficacy and safety of benmelstobart (a novel programmed death-ligand 1 (PD-L1) inhibitor) with anlotinib (a multi-target anti-angiogenic small molecule) and standard chemotherapy in treatment-naive ES-SCLC. The ETER701 trial assessed two primary endpoints: Independent Review Committee-assessed progression-free survival per RECIST 1.1 and overall survival (OS). Here the prespecified final progression-free survival and interim OS analysis is reported. Patients randomly received benmelstobart and anlotinib plus etoposide/carboplatin (EC; n = 246), placebo and anlotinib plus EC (n = 245) or double placebo plus EC ('EC alone'; n = 247), followed by matching maintenance therapy. Compared with EC alone, median OS was prolonged with benmelstobart and anlotinib plus EC (19.3 versus 11.9 months; hazard ratio 0.61; P = 0.0002), while improvement of OS was not statistically significant with anlotinib plus EC (13.3 versus 11.9 months; hazard ratio 0.86; P = 0.1723). The incidence of grade 3 or higher treatment-related adverse events was 93.1%, 94.3% and 87.0% in the benmelstobart and anlotinib plus EC, anlotinib plus EC, and EC alone groups, respectively. This study of immunochemotherapy plus multi-target anti-angiogenesis as first-line treatment achieved a median OS greater than recorded in prior randomized studies in patients with ES-SCLC. The safety profile was assessed as tolerable and manageable. Our findings suggest that the addition of anti-angiogenesis therapy to immunochemotherapy may represent an efficacious and safe approach to the management of ES-SCLC. ClinicalTrials.gov identifier: NCT04234607 .

摘要

免疫化疗是广泛期小细胞肺癌(ES-SCLC)的一线标准治疗方法。联合该方案与抗血管生成治疗可能会提高疗效。ETER701 是一项多中心、双盲、随机、安慰剂对照的 3 期临床试验,旨在研究贝美司他(一种新型程序性死亡配体 1(PD-L1)抑制剂)联合安罗替尼(一种多靶点抗血管生成小分子)与标准化疗在未经治疗的 ES-SCLC 患者中的疗效和安全性。ETER701 试验评估了两个主要终点:独立审查委员会根据 RECIST 1.1 评估的无进展生存期和总生存期(OS)。本文报告了预设的最终无进展生存期和中期 OS 分析结果。患者随机接受贝美司他和安罗替尼联合依托泊苷/卡铂(EC;n=246)、安慰剂和安罗替尼联合 EC(n=245)或双安慰剂联合 EC(“EC 单药”;n=247),随后进行匹配维持治疗。与 EC 单药相比,贝美司他和安罗替尼联合 EC 组的中位 OS 延长(19.3 个月比 11.9 个月;风险比 0.61;P=0.0002),而安罗替尼联合 EC 组的 OS 改善无统计学意义(13.3 个月比 11.9 个月;风险比 0.86;P=0.1723)。贝美司他和安罗替尼联合 EC、安罗替尼联合 EC 和 EC 单药组治疗相关不良事件的发生率分别为 93.1%、94.3%和 87.0%,其中 3 级或以上不良事件发生率分别为 56.4%、62.4%和 49.2%。这项免疫化疗联合多靶点抗血管生成作为一线治疗的研究在 ES-SCLC 患者中取得了中位 OS 大于既往随机研究的记录。安全性评估为可耐受和可控。我们的研究结果表明,将抗血管生成治疗联合免疫化疗可能是治疗 ES-SCLC 的一种有效且安全的方法。临床试验标识符:NCT04234607。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b194/11485241/56b6e82cb1ea/41591_2024_3132_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验